Ampersand Biomedicines is a series b startup. 1 investor tracked.
Ampersand Biomedicines is a startup based in the United States. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
Ampersand Biomedicines develops programmable medicines that target and act precisely at the site of disease, minimizing effects on healthy tissue. The company's Address, Navigate, Determine (AND) Platform combines computational tools and biological insights to create AND-Body Therapeutics.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.